Study of MLN8237 in Participants With Advanced Solid Tumors
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purposes of this study were to estimate the relative (Rel) bioavailability (BA) of an
oral solution (OS) formulation of alisertib in reference to a powder-in-capsule (PIC)
formulation, to characterize the effect of food on the single-dose pharmacokinetics (PK) of
alisertib OS and enteric-coated tablets (ECT), to characterize the multiple-dose safety,
tolerability, and steady-state PK of alisertib administered as an OS, and to characterize the
multiple-dose safety and tolerability of alisertib administered as an ECT.